Bristol Myers Squibb growth portfolio hits 60% of revenue after Q2 profit surge
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-21. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Growth portfolio revenue expansion to 60% offsets legacy LOE patent cliff earnings drag, supporting BMY forward multiple rerating.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factBristol Myers Squibb shares have gained 17% year-to-date following Q2 2026 revenue of $12.9 billion. |
| What else was confirmed? | Reported factThe company reported 153% year-over-year EPS growth in Q2. |
| Does the valuation support acting? | Interpretation1 stored valuation assumptions for BMY; the latest is dated 2026-08-06. |
| What would change the assessment? | UnknownBMY commercial drug uptake metrics — Quarterly prescription volume trajectories for growth portfolio therapies. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Bristol Myers Squibb shares have gained 17% year-to-date following Q2 2026 revenue of $12.9 billion.
- · The company reported 153% year-over-year EPS growth in Q2.
- · BMY's growth portfolio of newer commercial drugs grew 15% year-over-year and now accounts for nearly 60% of total company revenue.
Public research record
Research framework · page evidenceCompleted event assessment
patent expiration risk mitigation through high-margin growth drug mix
| Type | Claim | Scope |
|---|---|---|
| Assumption | Bristol Myers Squibb shares have gained 17% year-to-date following Q2 2026 revenue of $12.9 billion. | 2026-09-21 |
| Interpretation | patent expiration risk mitigation through high-margin growth drug mix | BMY |
Countercase, invalidators, and sources
Continued double-digit growth in commercial portfolio fully bridges loss-of-exclusivity revenue gaps.
- · BMY commercial drug uptake metrics — Quarterly prescription volume trajectories for growth portfolio therapies.
- Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder · 2026-09-20
What remains unresolved
- Base path
- Growth assets maintain a ~60% revenue share with steady operating margin performance.
- Adverse path
- Competitive clinical entries in newer indications slow the 15% growth trajectory.
- Supportive path
- Continued double-digit growth in commercial portfolio fully bridges loss-of-exclusivity revenue gaps.
- · BMY commercial drug uptake metrics — Quarterly prescription volume trajectories for growth portfolio therapies.this week
Evidence
- Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder2026-09-20
“Bristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year.”
Supports: BMY Q2 revenue reached $12.9B, EPS up 153%, growth portfolio represents 60% of revenue growing 15% YoY.